Cargando…
Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
BACKGROUND: Patients with myeloproliferative neoplasms (MPNs) suffer from chronic and progressive symptom burden. MPN trials capturing patient-reported symptoms routinely administer the MPN Symptom Assessment Form (SAF). The MPN-10 assesses 10 of the most clinically relevant symptoms, including fati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577588/ https://www.ncbi.nlm.nih.gov/pubmed/34804309 http://dx.doi.org/10.14740/jh914 |
_version_ | 1784596090313506816 |
---|---|
author | Langlais, Blake T. Mazza, Gina L. Kosiorek, Heidi E. Palmer, Jeanne Mesa, Ruben Dueck, Amylou C. |
author_facet | Langlais, Blake T. Mazza, Gina L. Kosiorek, Heidi E. Palmer, Jeanne Mesa, Ruben Dueck, Amylou C. |
author_sort | Langlais, Blake T. |
collection | PubMed |
description | BACKGROUND: Patients with myeloproliferative neoplasms (MPNs) suffer from chronic and progressive symptom burden. MPN trials capturing patient-reported symptoms routinely administer the MPN Symptom Assessment Form (SAF). The MPN-10 assesses 10 of the most clinically relevant symptoms, including fatigue and generates a Total Symptom Score (TSS). The original MPN-10 included a fatigue item from the Brief Fatigue Inventory (BFI). The myelofibrosis-specific symptom assessment tool called the MFSAF v4 utilizes a fatigue item developed to be consistent with other items within the SAF. This study sought to validate a modified version of the MPN-10 TSS using the SAF fatigue item for harmonization with MFSAF v4. METHODS: Survey data from two cohorts of patients with essential thrombocythemia, polycythemia vera, or myelofibrosis assessing MPN characteristics and symptom burden were used. RESULTS AND CONCLUSION: BFI and SAF fatigue items were highly correlated in raw score (Pearson r = 0.88), comparable in their severity categorizations (89% agreement for severe versus non-severe) and respective contributions to the TSS (both Cronbach’s alpha = 0.89). Reliability of SAF fatigue was acceptable and independently associated with known disease-related characteristics (splenomegaly, low quality-of-life, and distress). Fatigue in patients with MPNs is measured with high similarity using the SAF fatigue item within the MPN-10 in harmonization with the MFSAF v4. |
format | Online Article Text |
id | pubmed-8577588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-85775882021-11-18 Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score Langlais, Blake T. Mazza, Gina L. Kosiorek, Heidi E. Palmer, Jeanne Mesa, Ruben Dueck, Amylou C. J Hematol Original Article BACKGROUND: Patients with myeloproliferative neoplasms (MPNs) suffer from chronic and progressive symptom burden. MPN trials capturing patient-reported symptoms routinely administer the MPN Symptom Assessment Form (SAF). The MPN-10 assesses 10 of the most clinically relevant symptoms, including fatigue and generates a Total Symptom Score (TSS). The original MPN-10 included a fatigue item from the Brief Fatigue Inventory (BFI). The myelofibrosis-specific symptom assessment tool called the MFSAF v4 utilizes a fatigue item developed to be consistent with other items within the SAF. This study sought to validate a modified version of the MPN-10 TSS using the SAF fatigue item for harmonization with MFSAF v4. METHODS: Survey data from two cohorts of patients with essential thrombocythemia, polycythemia vera, or myelofibrosis assessing MPN characteristics and symptom burden were used. RESULTS AND CONCLUSION: BFI and SAF fatigue items were highly correlated in raw score (Pearson r = 0.88), comparable in their severity categorizations (89% agreement for severe versus non-severe) and respective contributions to the TSS (both Cronbach’s alpha = 0.89). Reliability of SAF fatigue was acceptable and independently associated with known disease-related characteristics (splenomegaly, low quality-of-life, and distress). Fatigue in patients with MPNs is measured with high similarity using the SAF fatigue item within the MPN-10 in harmonization with the MFSAF v4. Elmer Press 2021-10 2021-10-31 /pmc/articles/PMC8577588/ /pubmed/34804309 http://dx.doi.org/10.14740/jh914 Text en Copyright 2021, Langlais et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Langlais, Blake T. Mazza, Gina L. Kosiorek, Heidi E. Palmer, Jeanne Mesa, Ruben Dueck, Amylou C. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score |
title | Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score |
title_full | Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score |
title_fullStr | Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score |
title_full_unstemmed | Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score |
title_short | Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score |
title_sort | validation of a modified version of the myeloproliferative neoplasm symptom assessment form total symptom score |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577588/ https://www.ncbi.nlm.nih.gov/pubmed/34804309 http://dx.doi.org/10.14740/jh914 |
work_keys_str_mv | AT langlaisblaket validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore AT mazzaginal validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore AT kosiorekheidie validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore AT palmerjeanne validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore AT mesaruben validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore AT dueckamylouc validationofamodifiedversionofthemyeloproliferativeneoplasmsymptomassessmentformtotalsymptomscore |